Know Labs, Inc.

Equities

KNW

US4992381032

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 21:00:00 17/07/2024 BST			5-day change	1st Jan Change
0.4245 ^USD	0.00%		+12.30%	-16.60%

07-11	Know Labs, Inc. Publishes Clinical Results in Leading Diabetes Journal	CI
06-22	Know Labs, Inc. Announces Further Interim Results from a Clinical Research Study	CI

KNOW LABS, INC. : Other Events (form 8-K)

January 05, 2022 at 02:03 pm

Item 8.01 Other Events

On January 5, 2022, Know Labs, Inc. a Nevada corporation (the "Company"), released three YouTube videos, which show interviews with key members of management, Ronald P. Erickson, Chairman of the Board, Phillip Bosua, Chief Executive Officer and Leonardo Trautwein, Chief Marketing Officer. Please see the YouTube Videos at the following links; https://youtu.be/hHVbAUeps-k, https://youtu.be/7waq1tHCbuk, and https://youtu.be/OQhtQFCY1F4.

Latest news about Know Labs, Inc.

Know Labs, Inc. Publishes Clinical Results in Leading Diabetes Journal	07-11	CI
Know Labs, Inc. Announces Further Interim Results from a Clinical Research Study	06-21	CI
Know Labs, Inc. Announces the Appointment of Chris Somogyi as President, International	05-16	CI
Transcript : Know Labs, Inc., Q2 2024 Earnings Call, May 15, 2024	05-15
Know Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-15	CI
Know Labs, Inc. to Present Clinical Research At the 2024 American Association of Clinical Endocrinology Annual Meeting	05-09	CI
Certain Common Stock of Know Labs, Inc. are subject to a Lock-Up Agreement Ending on 27-MAR-2024.	03-26	CI
Know Labs, Inc. Announces Interim Results from its Most Recent Clinical Research Study	03-06	CI
Know Labs, Inc. announced that it expects to receive $12 million in funding from The Lind Partners, LLC	02-26	CI
Transcript : Know Labs, Inc., Q1 2024 Earnings Call, Feb 14, 2024	02-14
Know Labs, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-14	CI
Know Labs, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	12-19	CI
Transcript : Know Labs, Inc., Q4 2023 Earnings Call, Dec 19, 2023	12-19
Know Labs, Inc. Announces Board Appointments	12-14	CI
Know Labs, Inc. Expands Board of Directors	11-08	CI
Transcript : Know Labs, Inc., Q3 2024 Earnings Call, Aug 14, 2023	14/08/23
Know Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	14/08/23	CI
Know Labs, Inc. Demonstrates Improved Accuracy of Machine Learning Model for Non-Invasive Glucose Monitor	26/07/23	CI
Know Labs Completes Build of Portable Generation 1 Prototype for Non-Invasive Glucose Monitoring	07/06/23	CI
Know Labs, Inc. Furthers External Validation of Bio-RFID(TM) Technology with Study Published in Sensors Journal	18/05/23	CI
Know Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	15/05/23	CI
Know Labs, Inc. Study Validates Technical Feasibility of Its Novel Sensor for Non-Invasive Glucose Monitoring	05/05/23	CI
Know Labs, Inc. Announces Board Appointments	22/03/23	CI
Certain Warrants of Know Labs, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2023.	20/03/23	CI
Certain Convertible Debentures of Know Labs, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2023.	20/03/23	CI

Chart Know Labs, Inc.

Duration

Period

More charts

Company Profile

Know Labs, Inc. is a provider of non-invasive blood glucose monitoring solutions. The Company is focused on the development and commercialization of its proprietary sensor technology utilizing radio and microwave spectroscopy. When paired with its machine learning platform, the Companyâs Bio-RFID sensor technology platform identifies and measures various material or analyte using electromagnetic energy to detect, record, identify and measure the signature of said materials or analytes. The data obtained with its sensor technology is analyzed with the Companyâs trade secret algorithms. The Company is focused on analytes relating to human health, the identification, of which provide diagnostic information and require, by their nature, clearance by the United States Food and Drug Administration. The first among those analytes is the non-invasive monitoring of blood glucose levels. Its device provides the user with real-time information on their blood glucose levels.

Sector

Advanced Medical Equipment & Technology

Calendar

10/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4245 USD

Average target price

1 USD

Spread / Average Target

+135.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

	1st Jan change	Capi.
KNOW LABS, INC.	-16.60%	36.3M
VEEVA SYSTEMS INC.	-5.50%	30.25B
PRO MEDICUS LIMITED	+40.35%	9.47B
SECTRA AB	+31.81%	4.33B
EVOLENT HEALTH, INC.	-36.88%	2.49B
VERADIGM INC.	-6.48%	1.66B
OMNICELL, INC.	-23.84%	1.27B
LUNIT INC.	-42.92%	972M
SIMULATIONS PLUS, INC.	-3.96%	885M
B-SOFT CO.,LTD.	-50.69%	687M

Medical Software & Technology Services